Goldman Sachs Group Inc Eledon Pharmaceuticals, Inc. Transaction History
Goldman Sachs Group Inc
- $613 Billion
- Q4 2024
A detailed history of Goldman Sachs Group Inc transactions in Eledon Pharmaceuticals, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 144,845 shares of ELDN stock, worth $621,385. This represents 0.0% of its overall portfolio holdings.
Number of Shares
144,845Holding current value
$621,385% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ELDN
# of Institutions
77Shares Held
37.2MCall Options Held
17KPut Options Held
2.7K-
Bvf Inc San Francisco, CA6.29MShares$27 Million0.96% of portfolio
-
Ra Capital Management, L.P. Boston, MA3.57MShares$15.3 Million0.24% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.89MShares$12.4 Million0.0% of portfolio
-
Sphera Funds Management Ltd. Tel Aviv, L32.55MShares$10.9 Million2.15% of portfolio
-
First Light Asset Management, LLC Edina, MN2.33MShares$9.99 Million0.93% of portfolio
About Eledon Pharmaceuticals, Inc.
- Ticker ELDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 13,756,800
- Market Cap $59M
- Description
- Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that i...